Methodological issues in pharmacokinetic-pharmacodynamic modelling
- PMID: 9739481
- DOI: 10.2165/00003088-199835020-00004
Methodological issues in pharmacokinetic-pharmacodynamic modelling
Abstract
This article presents the theoretical and practical aspects involved in the design and analysis of pharmacokinetic-pharmacodynamic modelling studies. The main features of the protocol of pharmacokinetic-pharmacodynamic studies are discussed with special focus on experimental designs in relation to individual and population approaches. Some basic pharmacodynamic models (such as linear, log-linear, hyperbolic and sigmoid models) are presented as well as more complex time-dependent models (effect compartment and physiological indirect response, tolerance models) which are required when the concentration-effect relationship shows a hysteresis loop. The methods of estimation, with special focus on the individual and populations approaches, are covered, along with the way pharmacodynamic models and methods of estimation can be applied to real data and the information required to criticise the results of modelling. We also present some real problems frequently encountered when performing pharmacokinetic-pharmacodynamic modelling and give some potential solutions (problems with hysteresis loops, lack of convergence, problems with residuals). The last section discusses the significance of pharmacodynamic parameters.
Similar articles
-
Basic concepts of pharmacokinetic/pharmacodynamic (PK/PD) modelling.Int J Clin Pharmacol Ther. 1997 Oct;35(10):401-13. Int J Clin Pharmacol Ther. 1997. PMID: 9352388 Review.
-
Facilitation of drug evaluation in children by population methods and modelling.Clin Pharmacokinet. 2008;47(4):231-43. doi: 10.2165/00003088-200847040-00002. Clin Pharmacokinet. 2008. PMID: 18336053 Review.
-
Understanding the hysteresis loop conundrum in pharmacokinetic/pharmacodynamic relationships.J Pharm Pharm Sci. 2014;17(1):34-91. J Pharm Pharm Sci. 2014. PMID: 24735761 Free PMC article.
-
Pharmacokinetic-pharmacodynamic modelling: history and perspectives.J Pharmacokinet Pharmacodyn. 2006 Jun;33(3):227-79. doi: 10.1007/s10928-005-9002-0. Epub 2006 Jan 11. J Pharmacokinet Pharmacodyn. 2006. PMID: 16404503 Review.
-
A semi-compartmental model describing the pharmacokinetic-pharmacodynamic relationship.Anesth Pain Med (Seoul). 2020 Jan 31;15(1):1-7. doi: 10.17085/apm.2020.15.1.1. Anesth Pain Med (Seoul). 2020. PMID: 33329783 Free PMC article. Review.
Cited by
-
Adaptive control methods for the dose individualisation of anticancer agents.Clin Pharmacokinet. 2000 Apr;38(4):315-53. doi: 10.2165/00003088-200038040-00003. Clin Pharmacokinet. 2000. PMID: 10803455 Review.
-
Pharmacokinetic-pharmacodynamic model for perindoprilat regional haemodynamic effects in healthy volunteers and in congestive heart failure patients.Br J Clin Pharmacol. 2001 Jul;52(1):25-33. doi: 10.1046/j.0306-5251.2001.01410.x. Br J Clin Pharmacol. 2001. PMID: 11453887 Free PMC article. Clinical Trial.
-
Comparison of stepwise and simultaneous estimations of population pharmacokinetics and pharmacodynamics of TS-943.Eur J Drug Metab Pharmacokinet. 2003 Jul-Sep;28(3):191-9. doi: 10.1007/BF03190485. Eur J Drug Metab Pharmacokinet. 2003. PMID: 14527092
-
Bayesian estimation of methotrexate pharmacokinetic parameters and area under the curve in children and young adults with localised osteosarcoma.Clin Pharmacokinet. 2002;41(13):1095-104. doi: 10.2165/00003088-200241130-00006. Clin Pharmacokinet. 2002. PMID: 12403645 Clinical Trial.
-
Integrated pharmacokinetics and pharmacodynamics in drug development.Clin Pharmacokinet. 2007;46(9):713-37. doi: 10.2165/00003088-200746090-00001. Clin Pharmacokinet. 2007. PMID: 17713971 Review.
References
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources